David Price, Christine Jenkins, Kerry Hancock, Rebecca Vella, Florian Heraud, Porsche Le Cheng, Ruth Murray, Maarten Beekman, Sinthia Bosnic-Anticevich, Fabio Botini, Victoria Carter, Angelina Catanzariti, Joe Doan, Kirsty Fletton, Ata Kichkin, Thao Le, Chantal Le Lievre, Chi Ming Lau, Dominique Novic, John Pakos, Kanchanamala Ranasinghe, Alexander Roussos, Josephine Samuel-King, Anita Sharma, Deb Stewart, Bruce Willet, Eric Bateman
INTRODUCTION: In Australia, short-acting β2 -agonists (SABA) are available both over the counter (OTC) and on prescription. This ease of access may impact SABA use in the Australian population. Our aim was to assess patterns and outcome associations of prescribed, acquired OTC and reported use of SABA by Australians with asthma. METHODS: This was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA)...
February 4, 2024: Advances in Therapy